Effectiveness and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus: A Multicenter, Prospective, Observational Study
Evogliptin reduces blood glucose levels and is well-tolerated when used as an add-on, as a switch from other dipeptidyl peptidase 4 inhibitors, or as part of an initial combination therapy in patients with type 2 diabetes mellitus.
Authors
- Jie-Eun Lee (ORCID: https://orcid.org/0000-0002-1039-5769)
- K. Park
- Baek Ki-Hyun
- Sung Hoon Yu (ORCID: https://orcid.org/0000-0002-9524-5224)
- Hyung-Wook Kim
- Koon Soon Kim (ORCID: https://orcid.org/0000-0002-5545-2093)
- Ji Hoon Kim (ORCID: https://orcid.org/0000-0002-4427-3997)
- Jung Han Kim (ORCID: https://orcid.org/0000-0002-9134-1761)
- Jun Hwa Hong
- Min Soo Song
- Yong Hwan Lee
- JaeMyung Yu
- Seung Jin Lee
- Jong Chul Won
- KyungWan Min
Institutions
- Daejeon University (KR)
- Eulji University (KR)
- Soonchunhyang University (KR)
- The Catholic University of Korea St. Vincent's Hospital (KR)
- Hallym University Kangnam Sacred Heart Hospital (KR)
- The Catholic University of Korea Yeouido St. Mary's Hospital (KR)
- Sungae Hospital (KR)
- Kimpo University (KR)
- BongSeng Memorial Hospital (KR)
- Hanyang University Guri Hospital (KR)
- Bumin Hospital Group (KR)
- CHA University Gangnam Medical Center (KR)
- Asan Foundation (KR)
- Hongik University (KR)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1111/dom.70601
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00